Laurus Labs (LAURUS)’s Annual Report Analysis indicates a sharp improvement in ROE, led by a strong head-start in Finished dosage forms (FDF), improving operating profit, and a reduced interest rate, the brokerages have upgraded their target as well;
sail has formed a cup and handle formation and I think the stock is ready for an upward move considering the stellar results as well
Target 1-2850, 2-3200 great earnings, Amid challenges owing to Covid-19 and related uncertainties, the company is confident of achieving >15% growth in FY22
might test the trendline supports as it has breached the earlier bo levels,